Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems

Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery

In this work the potential of chitosan nanoparticles (CNP) and thermosensitive chitosan hydrogels as particulate and sustained release vaccine delivery systems was investigated. CNP and chitosan hydrogels were prepared, loaded with the model protein antigen ovalbumin (OVA) and characterised. The immunostimulatory capacity of these vaccine delivery systems was assessed in-vitro and in-vivo. Particle sizing measurements and SEM images showed that optimised OVA-loaded CNP had a size of approximately 200 nm, a polydispersity index < 0.2, and a positive zeta-potential of approximately 18 mV. The amount of OVA adsorbed onto CNP was high with an adsorption efficacy of greater than 96%. Raman spectroscopy indicated conformational changes of OVA when adsorbed onto the surface of CNP. Uptake of the dispersions and immunological activation of murine dendritic cells in-vitro could be demonstrated. Investigation of the release of fluorescently-labelled OVA (FITC-OVA) from CNP and chitosan hydrogels in-vitro showed that approximately 50% of the total protein was released from CNP within a period of ten days; release of antigen from chitosan gel occurred in a more sustained manner, with < 10% of total protein being released after 10 days. The slow release from gel formulations may be explained by the strong interactions of the protein with chitosan. While OVA-loaded CNP showed no significant immunogenicity, formulations of OVA in chitosan gel were able to stimulate both cell-mediated and humoral immunity in-vivo.

Recent advances in the field of nanometric drug carriers

Over the past few years, health and medicine have been domains where nanotechnologies have shown great promise, in particular in the area of drug carriers and drug targeting. Many active substances suffer from poor solubility, instability in biological medium and low bioavailability. Inaccurate distribution and accumulation of the drug in the body could lead to some side effects possibly detrimental to drug development. With the advent of nanosciences applied to medicine, new tools are becoming available, giving rise to a whole range of drug carriers with different properties and functionalities. Nanocarriers should play a crucial role in the controlled and sustained delivery of drugs. Various types of functional nanosystems are currently being explored and the aim of this review is to give an overview of the most recent advances in the field of nanometric drug carriers, including future strategies and perspectives.

Cytochrome C on silica nanoparticles: influence of nanoparticle size on protein structure, stability, and activity

The structure, thermodynamic and kinetic stability, and activity of cytochrome c (cyt c) on silica nanoparticles (SNPs) of different sizes have been studied. Adsorption of cyt c onto larger SNPs results in both greater disruption of the cyt c global structure and more significant changes of the local heme microenvironment than upon adsorption onto smaller SNPs. The disruption of the heme microenvironment leads to a more solvent-accessible protein active site, as suggested by Soret circular dichroism spectroscopy and through an increase in peroxidase activity as a function of increased SNP size. Similarly, the stability of cyt c decreases more dramatically upon adsorption onto larger SNPs. These results are consistent with changes in protein-nanoparticle interactions that depend on the size or surface curvature of the supporting nanostructure. This study provides further fundamental insights into the effects of nanoscale surfaces on adsorbed protein structure and function.

Methods for the preparation and manufacture of polymeric nanoparticles

This review summarizes the different methods of preparation of polymer nanoparticles including nanospheres and nanocapsules. The first part summarizes the basic principle of each method of nanoparticle preparation. It presents the most recent innovations and progresses obtained over the last decade and which were not included in previous reviews on the subject. Strategies for the obtaining of nanoparticles with controlled in vivo fate are described in the second part of the review. A paragraph summarizing scaling up of nanoparticle production and presenting corresponding pilot set-up is considered in the third part of the review. Treatments of nanoparticles, applied after the synthesis, are described in the next part including purification, sterilization, lyophilization and concentration. Finally, methods to obtain labelled nanoparticles for in vitro and in vivo investigations are described in the last part of this review.

In vitro self-assembly of tailorable nanotubes from a simple protein building block

We demonstrate a method for generating discretely structured protein nanotubes from the simple ring-shaped building block, homohexameric Hcp1 from Pseudomonas aeruginosa. Our design exploited the observation that the crystal lattice of Hcp1 contains rings stacked in a repeating head-to-tail pattern. High-resolution detail of the ring-ring interface allowed the selection of sites for specific cysteine mutations capable of engaging in disulfide bond formation across rings, thereby generating stable Hcp1 nanotubes. Protein nanotubes containing up to 25 subunits ( approximately 100 nm in length) were self-assembled under simple conditions. Furthermore, we demonstrate that the tube ends and interior can be independently and specifically functionalized to generate nanocapsules.

Synthesis, penetrability and intracellular targeting of fluorescein-tagged peptoids and peptide-peptoid hybrids

The search for novel, generally applicable and highly efficient delivery tools is a major activity in the biotechnology arena. Using highly optimized microwave based solid-phase chemistry a series of fluorescein-labelled cationic peptoid conjugates were synthesized within 24h and cellular uptake into HeLa, L929 and K562 cells examined via flow cytometry. As expected, analysis revealed that longer oligomers achieved greater cellular penetration (7e (9 mer)>7d (7 mer)>7c (5 mer)>7b (3 mer)>7a (1 mer)) with the nonamer 7e proving to be a remarkable vehicle for all the cell lines, showing excellent penetrability into K562 and L929 cells and extraordinary cell delivery into HeLa cells. Confocal microscopy showed that the hybrid peptoid-nuclear localizing sequence (PKKKRKV from the simian virus 40 large T antigen) resulted in very high levels of nuclei delivery after 3h, opening up a range of applications such as nuclei staining of living cells with non-DNA-intercalating fluorescent probes.

Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery

Poly(alkylcyanoacrylate) (PACA) nanoparticles were first developed 25 years ago taking advantage of the in vivo degradation potential of the polymer and of its good acceptance by living tissues. Since then, various PACA nanoparticles were designed including nanospheres, oil-containing and water-containing nanocapsules. This made possible the in vivo delivery of many types of drugs including those presenting serious challenging delivery problems. PACA nanoparticles were proven to improve treatments of severe diseases like cancer, infections and metabolic disease. For instance, they can transport drugs across barriers allowing delivery of therapeutic doses in difficult tissues to reach including in the brain or in multidrug resistant cells. This review gives an update on the more recent developments and achievements on design aspects of PACA nanoparticles as delivery systems for various drugs to be administered in vivo by different routes of administration.

PEGylation: Posttranslational bioengineering of protein biotherapeutics

Polymer conjugation, especially by poly(ethylene glycol), has become a leading technology for the delivery of proteins. Nowadays, biotech drugs represent an increasing share of the new approved drugs, but their use is often prevented by drawbacks and safety concern. In particular, short in vivo half-life and immunogenicity are significant problems faced by the researchers dealing with the development of protein and peptide drugs. The chemical linking of a polymer to the protein surface has proved effective in prolonging protein blood circulation and reducing the immunogenicity by decreasing renal clearance and shielding immunogenic epitopes, respectively. So far, PEGylation has already led to nine marketed conjugates with great therapeutic success.:

Rise of the nanomachine: the evolution of a revolution in medicine

Although the current array of nanomachines mostly comprises simple devices (at least from a mechanical viewpoint), the underlying physical and chemical interactions that play key roles in the ‘assembly’ of these machines have required decades of research to ascertain a fundamental understanding of how such processes can be manipulated at the nanoscale. In this review, we wish to convey a realistic picture of the current developments in the design and implementation of nanomachines, with an emphasis on how these developments are leading to practical applications in medicine, including a sense of how such simple devices are rapidly becoming the building blocks for assembling the nanorobots of tomorrow.

Oral administration of peptides and proteins: nanoparticles and cyclodextrins as biocompatible delivery systems

This review discusses drawbacks to peptide and protein oral formulations related to these drugs’ chemical and physical instability. Means used to overcome such limitations are mentioned and discussed in parallel with manufacturing considerations, metabolism, absorption mechanisms and the efflux systems that peptides and proteins experience as they travel through the gastrointestinal tract. Special focus is given to the use of delivery systems based on nanoparticles and cyclodextrins. Advantages of these systems relate to the protection from degradation, enhancement of absorption, targeting and controlling the release of the drug. Biodistribution and safety issues are discussed once material from the delivery system is expected to be absorbed by the body and thus interact with biological components. Operating parameters regarding nanoparticle manufacture and composition are also overviewed since nanoparticle physicochemical characteristics influence the ability to successfully entrap the intended drug as well as interaction with body.